The earnings call reflects a strong financial and operational performance with significant revenue growth, market leadership, and pipeline advancements. Despite challenges in fixed-duration treatments and navigating a complex global environment, the company's strategic initiatives and investments are positioning it well for future growth.

Company Guidance -

Q2 2025

During the call, the company provided detailed guidance and updates across various metrics. For the first quarter of fiscal year 2025, they achieved revenue of $1.1 billion, marking a 49% growth compared to the previous year. The U.S. market saw a 60% increase, with BRUKINSA leading in new patient starts and achieving $563 million in sales, representing a 60% year-over-year growth. The company also achieved GAAP profitability for the first time, with significant improvements in operating profit and cash flow. They anticipate full-year revenue between $4.9 billion and $5.3 billion, maintaining a gross margin in the mid-80 percentile range. Additionally, they highlighted their robust pipeline progress, with over 10 proof-of-concept readouts expected across their solid tumor pipeline in 2025, and emphasized the strategic investments made to ensure supply chain resiliency, including an $800 million investment in a New Jersey manufacturing facility. The company also announced their redomiciling to Switzerland, reflecting their evolution into a globally diversified oncology leader.

Record-Breaking Revenue Growth

Global sales reached $1.1 billion in Q1 2025, marking a 49% increase from Q1 2024. The U.S. market alone grew by 60%, driven by strong demand for BRUKINSA.

BRUKINSA's Market Leadership

BRUKINSA became the market leader by revenue in the U.S. BTK market, with Q1 2025 sales reaching $563 million, a 60% growth compared to the previous year. It surpassed competitors in new patient starts for CLL.

GAAP Profitability Achieved

For the first time, the company achieved GAAP profitability, with net income showing significant improvement from the previous year.

Robust Pipeline Progress

The company is advancing a strong pipeline, including the BTK CDAC and sonro, with multiple Phase III trials initiated and more than 10 proof-of-concept readouts expected in 2025.

Global Expansion and Growth

Significant sales growth was seen in Europe (75% increase) and the rest of the world (146% increase), driven by new launches and market expansion.

BeOne Medicines (ONC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ONC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	0.32 / -	-1.15	―	―	―
May 07, 2025	2025 (Q1)	-0.53 / 0.00	-2.41	―
Mar 27, 2025	2024 (Q4)	-1.01 / -1.43	-3.53	59.49% (+2.10)
Nov 12, 2024	2024 (Q3)	-1.11 / -1.15	2.01	-157.21% (-3.16)		―
Aug 27, 2024	2024 (Q2)	-2.19 / -1.15	-3.64	68.41% (+2.49)	―	―
May 08, 2024	2024 (Q1)	-3.09 / -2.41	-3.34	27.84% (+0.93)		―
Feb 26, 2024	2023 (Q4)	-3.49 / -3.53	-4.29	17.72% (+0.76)	―	―
Nov 09, 2023	2023 (Q3)	-3.38 / 2.01	-5.39	137.29% (+7.40)	―	―
Aug 25, 2023	2023 (Q2)	-3.36 / -3.64	-5.56	34.53% (+1.92)	―	―
May 04, 2023	2023 (Q1)	-3.66 / -3.34	-4.24	21.23% (+0.90)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ONC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$241.75	$232.25	-3.93%
Mar 27, 2025	$250.92	$262.60	+4.65%
Nov 12, 2024	$205.04	$193.64	-5.56%
Aug 27, 2024	$199.22	$202.17	+1.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BeOne Medicines (ONC) report earnings?

BeOne Medicines (ONC) is schdueled to report earning on Aug 06, 2025, TBA (Confirmed).

What is BeOne Medicines (ONC) earnings time?

BeOne Medicines (ONC) earnings time is at Aug 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ONC EPS forecast?

ONC EPS forecast for the fiscal quarter 2025 (Q2) is 0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing